srch

Oct 25, 2021 · Targovax will at 14:00 CEST today host a live webcast presentation held by the company's newly appointed CEO Erik Digman Wiklund. ... and points to "commentary from management" indicating a ...

Jul 01, 2021 · Targovax ASA (OSE: TRVX) announces the appointment of Dr Lone Ottesen, MD, PhD as Chief Development Officer (CDO). She will take a leading role in driving the clinical programs forward. Dr Ottesen ...

Chief Executive Officer · Former consultant in the Pharma & Healthcare practice of McKinsey & Company, combined with a PhD in cancer research. Erik Digman ...

Targovax is a clinical stage immuno-oncology company developing immune ... You will provide leadership, direction and management of the finance and ...

Dec 20, 2021 · Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma. The median overall survival (mOS) was 25.0 months in the first-line group of patients treated with ...

The Board of Directors has resolved to grant 350,000 share options in the Company under the Company's long term incentive program, each with a ...

Following the grant Ola Melin holds no shares and 250,000 options in the Company. The options are granted without consideration. Pursuant to the ...

Sep 30, 2021 · Ola will be a member of Targovax's management team. Ola Melin joins Targovax with over 25 years' experience in Biologics development, manufacturing, and supply, most recently as Director of ...

Management Team. Former consultant in the Pharma & Healthcare practice of McKinsey & Company, combined with a PhD in cancer research. Erik Digman Wiklund was hired as the Company’s CFO in April 2017, and transitioned into the CBO role in October 2018. In October 2021 he was appinted CEO of Targovax. Dr.

Targovax ASA – Subsequent offering (08.07.2016) DNB Markets is acting as Joint Global Coordinator and Joint Bookrunner in relation to the subsequent offering in Targovax ASA (“Targovax” or the “Company”).

25.11.2021 · Carnegie AS and DNB Markets, a part of DNB Bank ASA, are acting as managers in the Rights Issue (jointly the "Managers"). Advokatfirmaet Thommessen AS is acting as legal counsel to the Company. For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@targovax.com. Renate Birkeli, Investor Relations

Management Team. Former consultant in the Pharma & Healthcare practice of McKinsey & Company, combined with a PhD in cancer research. Erik Digman Wiklund was hired as the Company’s CFO in April 2017, and transitioned into the CBO role in October 2018. In October 2021 he was appinted CEO of Targovax. Dr.

24.11.2021 · Targovax ASA announced its third quarter 2021 results on Thursday November 4, 2021. An online presentation by Targovax’s management to investors, analysts and the press will take place at 10:00 am CET.

Nov 04, 2021 · Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2021 results. Targovax's CEO ...

Targovax ASA - Fortrinnsrettsemisjon (29.11.2021) DNB Markets er en av tilretteleggerne for Targovax ASA i forbindelse med fortrinnsrettsemisjonen på Oslo Børs. DNB Markets is acting as Manager for Targovax ASA in relation to its rights issue on Oslo Stock Exchange.

Targovax is a clinical stage immuno-oncology company developing immune activators for ... An online presentation by Targovax's management to investors, ...

Anne-Kirsti Aksnes, PhD, VP Clinical Development, has 20 years of experience within clinical research and development in pharma and biotech ...

30.11.2021 · not for distribution or release, directly or indirectly, in or into the united states, canada, australia, the hong kong special administrative region of the people's republic of china or japan or any other jurisdiction in which the distribution or release would be unlawful. other restrictions are applicable. please see the important notice at the end of this stock exchange.

30.09.2021 · Targovax ASA (OSE: TRVX) announces the appointment of Ola Melin as Head of Manufacturing. He will take a leading role in driving Targovax's Chemistry, Manufacturing, and Controls (CMC) program ...

Nov 04, 2021 · Targovax ASA: Third quarter 2021 results. OSLO, Norway, Nov. 4, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to ...

04.11.2021 · Targovax ASA announced its third quarter 2021 results on Thursday November 4, 2021. An online presentation by Targovax’s management to investors, analysts and the press will take place at 10:00 am CET.

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors.

Ola will be a member of Targovax's management team. Ola Melin joins Targovax with over 25 years' experience in Biologics development, ...

25.10.2021 · Targovax will at 14:00 CEST today host a live webcast presentation held by the company's newly appointed CEO Erik Digman Wiklund.

16.12.2021 · Targovax ASA announced its third quarter 2021 results on Thursday November 4, 2021. An online presentation by Targovax’s management to investors, analysts and the press will take place at 10:00 am CET.

Managers: Carnegie AS and DNB Markets, a part of DNB Bank ASA ... Targovax aims to unlock greater clinical benefits in cancer patients by ...

Board member · Bente-Lill Bjerkelund Romøren is a consultant with 40 years' experience from national and international management positions in the pharmaceutical ...